No black box warning on record for Pioglitazone And Glimepiride

As of the latest FDA labeling reviewed, Pioglitazone And Glimepiride (PIOGLITAZONE AND GLIMEPIRIDE) does not carry a black box warning. Standard warnings and precautions still apply — see the full Pioglitazone And Glimepiride medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Congestive heart failure: Fluid retention may occur and can exacerbate or lead to congestive heart failure. Combination use with insulin and use in congestive heart failure NYHA Class I and II may increase risk. Monitor patients for signs and symptoms. ( 5.1 ) Hypoglycemia: May be severe. When insulin or an insulin secretagogue is used with pioglitazone, a lower dose of

No black box warning on record for Pioglitazone And Glimepiride

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Congestive heart failure: Fluid retention may occur and can exacerbate or lead to congestive heart failure. Combination use with insulin and use in congestive heart failure NYHA Class I and II may increase risk. Monitor patients for signs and symptoms. ( 5.1 ) Hypoglycemia: May be severe. When insulin or an insulin secretagogue is used with pioglitazone, a lower dose of

Pioglitazone And Glimepiride Black Box Warning

No black box warning on record for Pioglitazone And Glimepiride

Other warnings & precautions

Pioglitazone And Glimepiride Black Box Warning

No black box warning on record for Pioglitazone And Glimepiride

Other warnings & precautions